Research ExplorerPublicationsHereditary prostate cancer - Primetime for genetic testing?

Hereditary prostate cancer - Primetime for genetic testing?

Standard

Hereditary prostate cancer - Primetime for genetic testing? / EAU-YAU Prostate Cancer Working Group.

In: CANCER TREAT REV, Vol. 81, 12.2019, p. 101927.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

EAU-YAU Prostate Cancer Working Group 2019, 'Hereditary prostate cancer - Primetime for genetic testing?', CANCER TREAT REV, vol. 81, pp. 101927. https://doi.org/10.1016/j.ctrv.2019.101927

APA

EAU-YAU Prostate Cancer Working Group (2019). Hereditary prostate cancer - Primetime for genetic testing? CANCER TREAT REV, 81, 101927. https://doi.org/10.1016/j.ctrv.2019.101927

Vancouver

EAU-YAU Prostate Cancer Working Group. Hereditary prostate cancer - Primetime for genetic testing? CANCER TREAT REV. 2019 Dec;81:101927. https://doi.org/10.1016/j.ctrv.2019.101927

Bibtex

@article{663ece0cd8a8479990dbbf17dc30ad5f,
title = "Hereditary prostate cancer - Primetime for genetic testing?",
abstract = "Prostate cancer (PCa) remains the most common cancer in men. The proportion of all PCa attributable to high-risk hereditary factors has been estimated to 5-15%. Recent landmark discoveries in PCa genetics led to the identification of germline mutations/alterations (eg. BRCA1, BRCA2, ATM or HOXB13), single nucleotide polymorphisms or copy number variations associated with PCa incidence and progression. However, offering germline testing to men with an assumed hereditary component is currently controversial. In the present review article, we provide an overview about the epidemiology and the genetic basis of PCa predisposition and critically discuss the significance and consequence in the clinical routine. In addition, we give an overview about genetic tests and report latest findings from ongoing clinical studies. Lastly, we discuss the impact of genetic testing in personalized therapy in advanced stages of the disease.",
keywords = "BRCA1 Protein/genetics, BRCA2 Protein/genetics, Checkpoint Kinase 2/genetics, Clinical Trials as Topic, DNA Copy Number Variations, Genetic Predisposition to Disease, Genetic Testing, Homeodomain Proteins/genetics, Humans, Male, Mutation, Polymorphism, Single Nucleotide, Precision Medicine/methods, Prostatic Neoplasms/epidemiology",
author = "Isabel Heidegger and Igor Tsaur and Hendrik Borgmann and Christian Surcel and Alexander Kretschmer and Romain Mathieu and Visschere, {Pieter De} and Massimo Valerio and {van den Bergh}, {Roderick C N} and Piet Ost and Derya Tilki and Giorgio Gandaglia and Guillaume Ploussard and {EAU-YAU Prostate Cancer Working Group}",
note = "Copyright {\textcopyright} 2019 Elsevier Ltd. All rights reserved.",
year = "2019",
month = dec,
doi = "10.1016/j.ctrv.2019.101927",
language = "English",
volume = "81",
pages = "101927",
journal = "CANCER TREAT REV",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

RIS

TY - JOUR

T1 - Hereditary prostate cancer - Primetime for genetic testing?

AU - Heidegger, Isabel

AU - Tsaur, Igor

AU - Borgmann, Hendrik

AU - Surcel, Christian

AU - Kretschmer, Alexander

AU - Mathieu, Romain

AU - Visschere, Pieter De

AU - Valerio, Massimo

AU - van den Bergh, Roderick C N

AU - Ost, Piet

AU - Tilki, Derya

AU - Gandaglia, Giorgio

AU - Ploussard, Guillaume

AU - EAU-YAU Prostate Cancer Working Group

N1 - Copyright © 2019 Elsevier Ltd. All rights reserved.

PY - 2019/12

Y1 - 2019/12

N2 - Prostate cancer (PCa) remains the most common cancer in men. The proportion of all PCa attributable to high-risk hereditary factors has been estimated to 5-15%. Recent landmark discoveries in PCa genetics led to the identification of germline mutations/alterations (eg. BRCA1, BRCA2, ATM or HOXB13), single nucleotide polymorphisms or copy number variations associated with PCa incidence and progression. However, offering germline testing to men with an assumed hereditary component is currently controversial. In the present review article, we provide an overview about the epidemiology and the genetic basis of PCa predisposition and critically discuss the significance and consequence in the clinical routine. In addition, we give an overview about genetic tests and report latest findings from ongoing clinical studies. Lastly, we discuss the impact of genetic testing in personalized therapy in advanced stages of the disease.

AB - Prostate cancer (PCa) remains the most common cancer in men. The proportion of all PCa attributable to high-risk hereditary factors has been estimated to 5-15%. Recent landmark discoveries in PCa genetics led to the identification of germline mutations/alterations (eg. BRCA1, BRCA2, ATM or HOXB13), single nucleotide polymorphisms or copy number variations associated with PCa incidence and progression. However, offering germline testing to men with an assumed hereditary component is currently controversial. In the present review article, we provide an overview about the epidemiology and the genetic basis of PCa predisposition and critically discuss the significance and consequence in the clinical routine. In addition, we give an overview about genetic tests and report latest findings from ongoing clinical studies. Lastly, we discuss the impact of genetic testing in personalized therapy in advanced stages of the disease.

KW - BRCA1 Protein/genetics

KW - BRCA2 Protein/genetics

KW - Checkpoint Kinase 2/genetics

KW - Clinical Trials as Topic

KW - DNA Copy Number Variations

KW - Genetic Predisposition to Disease

KW - Genetic Testing

KW - Homeodomain Proteins/genetics

KW - Humans

KW - Male

KW - Mutation

KW - Polymorphism, Single Nucleotide

KW - Precision Medicine/methods

KW - Prostatic Neoplasms/epidemiology

U2 - 10.1016/j.ctrv.2019.101927

DO - 10.1016/j.ctrv.2019.101927

M3 - SCORING: Review article

C2 - 31783313

VL - 81

SP - 101927

JO - CANCER TREAT REV

JF - CANCER TREAT REV

SN - 0305-7372

ER -